Provided by Tiger Trade Technology Pte. Ltd.

SAB Biotherapeutics, Inc.

3.57
-0.2200-5.80%
Post-market: 3.570.00000.00%17:35 EST
Volume:123.87K
Turnover:451.75K
Market Cap:169.96M
PE:-1.60
High:3.85
Open:3.85
Low:3.55
Close:3.79
52wk High:6.60
52wk Low:1.00
Shares:47.61M
Float Shares:950.20K
Volume Ratio:0.43
T/O Rate:13.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2251
EPS(LYR):-3.6823
ROE:18.56%
ROA:-22.76%
PB:1.03
PE(LYR):-0.97

Loading ...

SAB Biotherapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Rita Jain

Reuters
·
Jan 08

SAB Biotherapeutics Initiated at Buy by UBS

Dow Jones
·
Jan 08

UBS Initiates SAB Biotherapeutics at Buy With $7 Price Target

MT Newswires Live
·
Jan 07

SAB Biotherapeutics Names David Zaccardelli as Board Chair and Rita Jain as Director

Reuters
·
Jan 07

SAB Bio Strengthens Board of Directors With Appointment of New Chair and New Director

THOMSON REUTERS
·
Jan 07

SAB Biotherapeutics Inc - David Zaccardelli Appointed as Chair of SAB Bio Board

THOMSON REUTERS
·
Jan 07

Press Release: SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

Dow Jones
·
Jan 07

SAB Biotherapeutics CEO to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 06

SAB Biotherapeutics Files $300 Million Mixed Shelf

MT Newswires Live
·
Dec 30, 2025

BRIEF-Sab Biotherapeutics Files For Offering Of Up To $300 Mln

Reuters
·
Dec 30, 2025

SAB Biotherapeutics Inc - Offering up to $300 Mln of Securities - SEC Filing

THOMSON REUTERS
·
Dec 30, 2025

BRIEF-SAB Biotherapeutics Enters Sales Agreement With UBS Securities - SEC Filing

Reuters
·
Dec 30, 2025

SAB Biotherapeutics Inc - Co May Offer and Sell From Time to Time Common Stock of up to $75 Mln - SEC Filing

THOMSON REUTERS
·
Dec 30, 2025

SAB Biotherapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Dec 19, 2025

Guggenheim Initiates Coverage on SAB Biotherapeutics With Buy Rating, $15 Price Target

MT Newswires Live
·
Dec 19, 2025

First Patient Dosed in SAB Bio’s Safeguard Clinical Trial of SAB-142 for the Treatment of Stage 3 T1d

THOMSON REUTERS
·
Dec 18, 2025

SAB Biotherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Dec 18, 2025

BRIEF-Sab Bio Announces Positive Confirmatory Clinical Results

Reuters
·
Dec 17, 2025

SAB Biotherapeutics Launches Phase 2b Trial of SAB-142 for Type 1 Diabetes

Reuters
·
Dec 17, 2025

SAB Biotherapeutics Inc - Phase 1 Data Confirms SAB-142 Does Not Cause Serum Sickness

THOMSON REUTERS
·
Dec 17, 2025